Wright Medical 10-Q 30 Apr 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 27, 2015
Document Information [Line Items]
Entity Registrant Name	WRIGHT MEDICAL GROUP INC
Entity Central Index Key	1137861
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		51,401,197
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$465,249	$227,326
Marketable securities	0	2,575
Accounts receivable, net	52,763	57,190
Inventories	101,876	88,412
Prepaid expenses	9,765	11,161
Deferred income taxes	4,885	3,437
Other current assets	50,662	50,355
Total current assets	685,200	440,456
Property, plant and equipment, net	108,852	104,235
Goodwill	184,724	190,966
Intangible assets, net	64,649	69,025
Deferred income taxes	730	815
Other assets	157,153	87,179
Total assets	1,201,308	892,676
Current liabilities:
Accounts payable	22,703	16,729
Accrued expenses and other current liabilities	170,415	170,204
Current portion of long-term obligations	733	718
Total current liabilities	193,851	187,651
Long-term debt and capital lease obligations	548,502	280,612
Deferred income taxes	12,977	11,566
Other liabilities	198,920	134,044
Total liabilities	954,250	613,873
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $.01 par value, authorized: 100,000,000 shares; issued and outstanding: 49,888,296 shares at March 31, 2014 and 47,993,765 shares at December 31, 2013	509	509
Additional paid-in capital	778,062	751,061
Accumulated other comprehensive income	-6,599	2,398
Retained earnings	-524,914	-475,165
Total stockholders' equity	247,058	278,803
Total liabilities and stockholders' equity	$1,201,308	$892,676

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets Parenthetical (USD $)	Mar. 31, 2015	Dec. 31, 2014
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Common Stock, Par or Stated Value Per Share (in dollars per share)	$0.01	$0.01
Common Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Common stock, issued and outstanding (in shares)	51,328,856	51,326,696

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net sales	$77,934	$71,062
Cost of sales	19,125	17,417
Gross profit	58,809	53,645
Operating expenses:
Selling, general and administrative	82,199	68,648
Research and development	7,117	5,856
Amortization of intangible assets	2,614	2,187
Total operating expenses	91,930	76,691
Operating (loss) income	-33,121	-23,046
Interest Expense Income, Net	7,649	4,136
Other (income) expense, net	5,312	15,286
Loss from continuing operations before income taxes	-46,082	-42,468
Benefit for income taxes	166	-12,170
Loss from Continuing Operations Attributable to Parent	-46,248	-30,298
(Loss) Income from Discontinued Operations, Net of Tax, Attributable to Parent	-3,500	-122
Net (loss) income	($49,748)	($30,420)
Net (loss) income per share (Note 11):
(Loss) income from Continuing Operations, Per Basic Share	($0.91)	($0.62)
(Loss) income from Continuing Operations, Per Diluted Share	($0.91)	($0.62)
Basic (in dollars per share)	($0.98)	($0.63)
Diluted (in dollars per share)	($0.98)	($0.63)
Weighted-average number of shares outstanding-basic (in shares)	50,868	48,625
Weighted-average number of shares outstanding, diluted (in shares)	50,868	48,625

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations Parenthetical (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation expense	$2,337	$2,320
Cost of sales [Member]
Stock-based compensation expense	3	111
Selling, general and administrative [Member]
Stock-based compensation expense	2,072	2,004
Research and Development Expense [Member]
Stock-based compensation expense	$262	$205

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net (loss) income	($49,748)	($30,420)
Other comprehensive income (loss), net of tax:
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	-8,997	-430
Reclassification of gain on equity securities, net of taxes of $1 and $3,041, respectively	0	2
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	0	-344
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax	0	2,628
Other Comprehensive Income (Loss), Net of Tax	-8,997	1,856
Comprehensive (loss) income	($58,745)	($28,564)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Comprehensive Income Parenthetical (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Reclassification Adjustment for Write-down of Securities Included in Net Income, Tax	$0	$1
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	$0	$0

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net (loss) income	($49,748,000)	($30,420,000)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation	5,280,000	4,346,000
Stock-based compensation expense	2,337,000	2,320,000
Consolidated Intangible Amortization	2,614,000	2,187,000
Amortization of deferred financing costs and debt discounts	1,297,000	2,676,000
Write off of Deferred Debt Issuance Cost	-24,746,000	0
Deferred income taxes	2,000	574,000
Non Cash Adjustment Derivative Fair Value	-6,935,000	1,000,000
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax	0	-24,277,000
Mark-to-market adjustment for CVRs (Note 1)	-13,454,000	14,295,000
Other	929,000	570,000
Changes in assets and liabilities (net of acquisitions):
Accounts receivable	3,149,000	-1,493,000
Inventories	-13,166,000	-3,911,000
Prepaid expenses and other assets	7,437,000	4,776,000
Accounts payable	6,351,000	6,747,000
Accrued expenses and other liabilities	3,915,000	-6,630,000
Net cash provided by operating activities	-25,246,000	-27,240,000
Investing activities:
Capital expenditures	-11,854,000	-7,836,000
Acquisition of businesses (Note 2)	0	-80,547,000
Purchase of intangible assets	-79,000	-755,000
Sales and maturities of available-for-sale marketable securities	2,566,000	1,745,000
Proceeds from Divestiture of Businesses	0	278,602,000
Net cash used in investing activities	-9,367,000	191,209,000
Financing activities:
Issuance of common stock	73,000	10,690,000
Proceeds from Issuance of Warrants	86,400,000	0
Derivative, Cost of Hedge	-144,843,000
Payments for Repurchase of Warrants	-59,803,000	0
Settlement of 2017 Notes Conversion Derivative	-49,152,000	0
Proceeds from Hedge, Financing Activities	69,764,000	0
Proceeds from Convertible Debt	632,500,000	0
Repayments of Convertible Debt	-240,000,000	0
Payments of deferred financing and equity issuance costs	-20,081,000	0
Payments of capital leases	-186,000	-26,000
Net cash provided by (used in) financing activities	274,672,000	10,664,000
Effect of exchange rates on cash and cash equivalents	-2,136,000	484,000
Net increase in cash and cash equivalents	237,923,000	175,117,000
Consolidated Cash and Equivalents, beginning of period	227,326,000	168,735,000
Consolidated Cash and Equivalents, end of period	465,249,000	343,852,000
2017 Notes Conversion Derivative [Member]
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Write off of Deferred Debt Issuance Cost	($24,700,000)

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group, Inc. have been prepared in accordance with accounting principles generally accepted (GAAP) in the United States (U.S.) for interim financial statements and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2015.
	In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year. Certain prior year amounts have been reclassified to conform with the current year presentation, including amounts related to discontinued operations.
	The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our domestic and international subsidiaries, all of which are wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
	The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the dates of the financial statements and the amounts of revenues and expenses during the reporting periods. Actual amounts realized or paid could differ from those estimates.
	Fair Value of Financial Instruments. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate the fair values of these financial instruments as of March 31, 2015 and December 31, 2014 due to their short maturities or variable rates.
	The outstanding $632.5 million of our 2.00% Convertible Senior Notes maturing in 2020 (2020 Notes) are carried at cost, net of unamortized discount. The estimated fair value of the 2020 Notes was approximately $664.5 million at March 31, 2015, based on a quoted price in an active market (Level 1).
	The remaining outstanding $60 million of our 2.00% Convertible Senior Notes maturing in 2017 (2017 Notes) are carried at cost, net of unamortized discount. The estimated fair value of the 2017 Notes was approximately $69.4 million at March 31, 2015, based on a quoted price in an active market (Level 1).
	FASB Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement, requires fair value measurements be classified and disclosed in one of the following three categories:
	Level 1: Financial instruments with unadjusted, quoted prices listed on active market exchanges.
	Level 2: Financial instruments determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
	Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.
	We use a third-party provider to determine fair values of our available-for-sale debt securities. The third-party provider receives market prices for each marketable security from a variety of industry standard data providers, security master files from large financial institutions and other third-party sources with reasonable levels of price transparency. The third-party provider uses these multiple prices as inputs into a pricing model to determine a weighted average price for each security. We have controls in place to review the third party provider's qualifications and procedures used to determine fair values and to validate the prices used in their determination of fair value. We classify our investment in U.S. Treasury bills and bonds and corporate equity securities as Level 1 based upon quoted prices in active markets. All other marketable securities are classified as Level 2 based upon the other than quoted prices with observable market data. These include U.S. agency debt securities, certificates of deposit, commercial paper, and corporate debt securities.
	During the third quarter of 2012, we issued $300 million of the 2017 Notes, and we recorded a derivative liability for the conversion feature (2017 Notes Conversion Derivative) of such 2017 Notes. Additionally, we entered into convertible notes hedging transactions (2017 Notes Hedges) in connection with the issuance of our 2017 Notes. On February 13, 2015, in connection with our issuance of the $632.5 million of the 2020 Notes, we used approximately $292 million of the net proceeds from the offering to repurchase approximately $240 million aggregate principal amount of our outstanding 2.00% cash convertible senior notes due 2017 in privately negotiated transactions, and settled all of the 2017 Notes Hedges. The 2017 Notes Conversion Derivative is measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs.
	On February 13, 2015, we issued $632.5 million of the 2020 Notes, and we have recorded a derivative liability for the conversion feature (2020 Notes Conversion Derivative) of such 2020 Notes. Additionally, we entered into convertible notes hedging transactions (2020 Notes Hedges) in connection with the issuance of the 2020 Notes. The 2020 Notes Hedges and the 2020 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs.
	To determine the fair value of the embedded conversion option in the 2017 Notes Conversion Derivative and 2020 Notes Conversion Derivative, a trinomial lattice model was used. A trinomial stock price lattice generates three possible outcomes of stock price - one up, one down, and one stable. This lattice generates a distribution of stock prices at the maturity date and throughout the life of the 2017 Notes and 2020 Notes. Using this stock price lattice, a convertible note lattice was created where the value of the embedded conversion option was estimated by comparing the value produced in a convertible note lattice with the option to convert against the value without the ability to convert. In each case, the convertible note lattice first calculates the possible convertible note values at the maturity date, using the distribution of stock prices, which equals to the maximum of (x) the remaining bond cash flows and (y) stock price times the conversion price. The values of the 2017 Notes Conversion Derivative and 2020 Notes Conversion Derivative at the valuation date was estimated using the values at the maturity date and moving back in time on the lattices (both for the lattice with the conversion option and without the conversion option). Specifically, at each node, if the 2017 Notes or 2020 Notes are eligible for early conversion, the value at this node is the maximum of (i) converting to stock, which is the stock price times the conversion price, and (ii) holding onto the 2017 Notes and 2020 Notes, which is the discounted and probability-weighted value from the three possible outcomes at the future nodes plus any accrued but unpaid coupons that are not considered at the future nodes. If the 2017 Notes or 2020 Notes are not eligible for early conversion, the value of the conversion option at this node equals to (ii). In the lattice, a credit adjustment was applied to the discount for each cash flow in the model as the embedded conversion option, as well as the coupon and notional payments, is settled with cash instead of shares.
	To estimate the fair value of the 2020 Notes Hedges, we used the Black-Scholes formula combined with credit adjustments, as the bank counterparties have credit risk and the call options are cash settled. We assumed that the call options will be exercised at the maturity since our common stock does not pay any dividends and management does not expect to declare dividends in the near term.
	The following assumptions were used in the fair market valuations of the 2017 Notes Conversion Derivative and 2020 Notes Conversion Derivative and 2020 Notes Hedges as of March 31, 2015:
		2017 Notes Conversion Derivative		2020 Notes Conversion Derivative		2020 Notes Hedge
	Stock Price Volatility (1)	35	%	35	%	35	%
	Credit Spread for Wright (2)	4.9	%	4.5	%	4.5	%
	Credit Spread for Deutsche Bank AG (3)	N/A		N/A		0.8	%
	Credit Spread for Wells Fargo Securities, LLC (3)	N/A		N/A		0.6	%
	-1	Volatility selected based on historical and implied volatility of common shares of Wright Medical Group, Inc.
	-2	Credit spread implied from traded price.
	-3	Credit spread of each bank is estimated using CDS curves. Source: Bloomberg.
	As part of the acquisitions of EZ Concepts Surgical Device Corporation, d/b/a EZ FrameTM and CCI® Evolution Mobile Bearing Total Ankle Replacement system (CCI acquisition), completed in 2010 and 2011, respectively, we have recorded $0.2 million of contingent liabilities for potential future cash payments related to these transactions as of March 31, 2015. The fair value of the contingent consideration associated with each of the acquisitions noted above as of March 31, 2015, was determined using a discounted cash flow model and probability adjusted estimates of the future earnings and is classified in Level 3. Changes in the fair value of contingent consideration are recorded in "Other expense (income), net" in our condensed consolidated statements of operations.
	As part of the acquisition of WG Healthcare in 2013, we have recorded contingent consideration of approximately $1.4 million as of March 31, 2015. The fair value of the contingent consideration associated with this acquisition as of March 31, 2015, was determined using a discounted cash flow model, utilizing a 12% discount rate and probability adjusted estimates of the future earnings and is classified in Level 3.
	On March 1, 2013, as part of the acquisition of BioMimetic Therapeutics, Inc. (BioMimetic), we issued Contingent Value Rights (CVRs) as part of the merger consideration. Each CVR entitles its holder to receive additional cash payments of up to $6.50 per share, which are payable upon receipt of FDA approval of Augment® Bone Graft and upon achieving certain revenue milestones. The fair value of the CVRs outstanding at March 31, 2015 of $120.5 million was determined using the closing price of the security in the active market (Level 1). For the three months ended March 31, 2015, the change in the value of the CVR resulted in a $13.5 million gain, which was recorded in Other expense (income) in the condensed consolidated statements of operations.
	The following table summarizes the valuation of our financial instruments measured at fair value on a recurring basis (in thousands):
		Total			Quoted Prices			Prices with			Prices with
					in Active			Other			Unobservable
					Markets			Observable			Inputs
					(Level 1)			Inputs			(Level 3)
								(Level 2)
	At March 31, 2015
	Assets
	Cash and cash equivalents	$	465,249		$	465,249		$	—		$	—
	Available-for-sale marketable securities
	Corporate debt securities	—			—			—			—
	U.S. government debt securities	—			—			—			—
	Total available-for-sale marketable securities	—			—			—			—
	2020 Notes Hedges	135,560			—			—			135,560
	Total	$	600,809		$	465,249		$	—		$	135,560
	Liabilities
	2017 Notes Conversion Derivative	$	13,431		$	—		$	—		$	13,431
	2020 Notes Conversion Derivative	136,748			—			—			136,748
	Contingent consideration	1,632			—						1,632
	Contingent consideration (CVR)	120,527			120,527			—			—
	Total	$	272,338		$	120,527		$	—		$	151,811
		Total			Quoted Prices			Prices with			Prices with
					in Active			Other			Unobservable
					Markets			Observable			Inputs
					(Level 1)			Inputs			(Level 3)
								(Level 2)
	At December 31, 2014
	Assets
	Cash and cash equivalents	$	227,326		$	227,326		$	—		$	—
	Available-for-sale marketable securities
	Corporate debt securities	566			—			566			—
	U.S. Government debt securities	2,009			2,009			—			—
	Total available-for-sale marketable securities	2,575			2,009			566			—
	2017 Notes Hedges	80,000			—			—			80,000
	Total	$	309,901		$	229,335		$	566		$	80,000
Liabilities
2017 Notes Conversion Derivative	$	76,000		$	—		$	—		$	76,000
Contingent consideration	1,705			—			—			1,705
Contingent consideration (CVR)	$	133,981		133,981			$	—		$	—
Total	$	211,686		$	133,981		$	—		$	77,705
The following is a roll forward of our assets and liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3):
		Balance at December 31, 2014			Transfers into Level 3		Gain/(Losses) included in Earnings		Currency		Settlements		Balance at March 31, 2015
2017 Notes Hedges		$	80,000		—		(10,236	)	—		(69,764	)	$	—
2017 Notes Conversion Derivative		$	(76,000	)	—		13,417		—		49,152		$	(13,431	)
2020 Notes Hedges		$	—		144,843		(9,283	)	—		—		$	135,560
2020 Notes Conversion Derivative		$	—		(149,784	)	13,036		—		—		$	(136,748	)
Contingent Consideration		$	(1,705	)	—		—		73		—		$	(1,632	)

Discontinued_Operations_Notes

Discontinued Operations (Notes)	3 Months Ended
	Mar. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Discontinued Operations
	On January 9, 2014, we completed our divestiture and sale of the OrthoRecon business to MicroPort Scientific Corporation (MicroPort). Pursuant to the terms of the asset purchase agreement (Purchase Agreement), the purchase price (as defined in the Purchase Agreement) for the OrthoRecon business was approximately $283 million (including a working capital adjustment), which MicroPort paid in cash. As a result of the transaction, we recognized approximately $24.3 million as the gain on disposal of the OrthoRecon business, before the effect of income taxes for the year ended December 31, 2014.
	All current and historical operating results for the OrthoRecon business are reflected within discontinued operations in the condensed consolidated financial statements. In addition, costs associated with corporate employees and infrastructure transferred as a part of the sale were included in discontinued operations. The following table summarizes the results of discontinued operations (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Revenue	$	—		$	2,942
	(Loss) income before tax (including $24.3 million gain from disposal in 2014)	(3,500		)	15,334
	Income tax (benefit) provision	—			15,456
	(Loss) income from discontinued operations, net of tax	(3,500		)	(122		)
	The 2014 effective tax rate within the results of discontinued operations reflects the sale of non-deductible goodwill of $25.8 million associated with the OrthoRecon business.
	Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee products sold prior to the closing, were not assumed by MicroPort. Charges associated with these product liability claims, including legal defense, settlements and judgments, income associated with product liability insurance recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results of discontinued operations, and we will continue to reflect these within results of discontinued operations in future periods. We will incur continuing cash outflows associated with legal defense costs and the ultimate resolution of these contingent liabilities, net of insurance proceeds, until these liabilities are resolved.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	8,435	$	6,910
	Work-in-process	20,216		13,849
	Finished goods	73,225		67,653
		$	101,876	$	88,412

Marketable_Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2015
Marketable Securities [Abstract]
Marketable Securities	Marketable Securities
	Our investments in marketable securities are classified as available-for-sale securities in accordance with FASB ASC Topic 320, Investments — Debt and Equity Securities. These securities are carried at their fair value, and all unrealized gains and losses are recorded within other comprehensive income. Marketable securities are classified as current for those expected to mature or be sold within 12 months and the remaining portion is classified as non-current. The cost of investment securities sold is determined by the specific identification method.
	As of March 31, 2015, we had no marketable securities. As of December 31, 2014, we had current marketable securities totaling $2.6 million, respectively, consisting of investments in corporate and government bonds, all of which are valued at fair value using a market approach.
	The following tables present a summary of our marketable securities as of December 31, 2014 (in thousands):
		Amortized Cost		Gross		Gross		Estimated
				Unrealized		Unrealized		Fair Value
				Gains		(Losses)
	At December 31, 2014
	Available-for-sale marketable securities
	Corporate debt securities	566		—		—		566
	U.S. government debt securities	2,009		—		—		2,009
	Total available-for-sale marketable securities	$	2,575	$	—	$	—	$	2,575

Property_Plant_and_Equipment_N

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
	Property, plant and equipment consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Property, plant and equipment, at cost	$	199,599		$	191,094
	Less: Accumulated depreciation	(90,747		)	(86,859		)
		$	108,852		$	104,235

LongTerm_Debt_and_Capital_Leas

Long-Term Debt and Capital Lease Obligations	3 Months Ended
	Mar. 31, 2015
Long-term Debt and Capital Lease Obligations [Abstract]
Long Term Debt and Capital Lease Obligations	Long-Term Debt and Capital Lease Obligations
	Long-term debt and capital lease obligations consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Capital lease obligations	$	8,492		$	8,678
	2017 Notes	55,012			272,652
	2020 Notes	485,731			—
		549,235			281,330
	Less: current portion	(733		)	(718		)
		$	548,502		$	280,612
	2017 Notes
	On August 31, 2012, we issued $300 million aggregate principal amount of the 2017 Notes pursuant to an indenture, dated as of August 31, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as Trustee. The 2017 Notes will mature on August 15, 2017, and we pay interest on the 2017 Notes semi-annually on each February 15 and August 15 at an annual rate of 2.00%. We may not redeem the 2017 Notes prior to the maturity date, and no “sinking fund” is available for the 2017 Notes, which means that we are not required to redeem or retire the 2017 Notes periodically. The 2017 Notes are convertible at the option of the holder, during certain periods and subject to certain conditions as described below, solely into cash at an initial conversion rate of 39.3140 shares per $1,000 principal amount of the 2017 Notes, subject to adjustment upon the occurrence of specified events, which represents an initial conversion price of $25.44 per share. The holder of the 2017 Notes may convert their notes at any time prior to February 15, 2017 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending December 31, 2012 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events, including during the period beginning 35 scheduled trading days prior to the anticipated effective date of our proposed merger with Tornier N.V. and ending 35 trading days after the actual effective date of such merger. While we currently do not expect significant conversions because the notes currently trade at a premium to the as-converted value, and a converting holder would forego future interest payments, any conversions would reduce our cash resources. On or after February 15, 2017 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2017 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2017 Notes, equal to the settlement amount as calculated under the indenture relating to the 2017 Notes. If we undergo a fundamental change, as defined in the indenture relating to the 2017 Notes, subject to certain conditions, holders of the 2017 Notes will have the option to require us to repurchase for cash all or a portion of their notes at a purchase price equal to 100% of the principal amount of the 2017 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the indenture relating to the 2017 Notes. In addition, following certain corporate transactions, we, under certain circumstances, will pay a cash make-whole premium by increasing the applicable conversion rate for a holder that elects to convert its 2017 Notes in connection with such corporate transaction. The 2017 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2017 Notes; (ii) equal in right of payment to any of our unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of this transaction, we recognized deferred financing charges of approximately $8.8 million, which are being amortized over the term of the 2017 Notes using the effective interest method.
	The 2017 Notes Conversion Derivative requires bifurcation from the 2017 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is accounted for as a derivative liability. The fair value of the 2017 Notes Conversion Derivative at the time of issuance of the 2017 Notes was $48.1 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2017 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2017 Notes. For the three months ended March 31, 2015, the Company recorded $1.4 million of interest expense related to the amortization of the debt discount based upon an effective rate of 6.47%.
	In connection with the 2020 Notes Offering, on February 13, 2015, we purchased and extinguished $240 million aggregate principal amount of the 2017 Notes. As a result of this transaction, we recognized approximately $24.7 million for the write off of related pro-rata unamortized deferred financing fees and debt discount within "Other expense (income), net" in our condensed consolidated statements of operations. As of March 31, 2015, $60 million aggregate principal amount of the 2017 Notes remain outstanding and is included within long-term obligations on the consolidated balance sheet.
	The components of the 2017 Notes were as follows (in thousands):
		March 31, 2015			December 31, 2014
	Principal amount of 2017 Notes	$	60,000		$	300,000
	Unamortized debt discount	(4,988		)	(27,348		)
	Net carrying amount of 2017 Notes	$	55,012		$	272,652
	2020 Notes
	On February 13, 2015, we issued $632.5 million aggregate principal amount of the 2020 Notes pursuant to an indenture, dated as of February 13, 2015 between us and The Bank of New York Mellon Trust Company, N.A., as Trustee. The 2020 Notes will pay interest semi-annually on each February 15 and August 15 at an annual rate of 2.00%, and will mature on February 15, 2020 unless earlier converted or repurchased. The 2020 Notes will be convertible, subject to certain conditions, solely into cash. The initial conversion rate for the 2020 Notes will be 32.3939 shares of common stock (subject to adjustment as provided in the Indenture) per $1,000 principal amount of the 2020 Notes (subject to, and in accordance with, the settlement provisions of the Indenture), which is equal to an initial conversion price of approximately $30.87 per share of common stock. We may not redeem the 2020 Notes prior to the maturity date, and no “sinking fund” is available for the 2020 Notes, which means that we are not required to redeem or retire the 2020 Notes periodically.
	The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2020 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. Our proposed merger with Tornier N.V. will not result in a conversion right for holders of the 2020 Notes. On or after August 15, 2019 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2020 Notes, equal to the settlement amount as calculated under the indenture relating to the 2020 Notes. If we undergo a fundamental change, as defined in the indenture relating to the 2020 Notes, subject to certain conditions, holders of the 2020 Notes will have the option to require us to repurchase for cash all or a portion of their notes at a purchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the indenture relating to the 2020 Notes. In addition, following certain corporate transactions, we, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2020 Notes in connection with such corporate transaction. The 2020 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2020 Notes; (ii) equal in right of payment to any of our unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of this transaction, we recorded deferred financing charges of approximately $18 million, which are being amortized over the term of the 2020 Notes using the effective interest method.
	The 2020 Notes Conversion Derivative requires bifurcation from the 2020 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is accounted for as a derivative liability. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2017 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2017 Notes. For the three months ended March 31, 2015, we recorded $3 million of interest expense related to the amortization of the debt discount based upon an effective rate of 8.54%.
	The components of the 2020 Notes were as follows (in thousands):
		31-Mar-15			31-Dec-14
	Principal amount of 2020 Notes	$	632,500		$	—
	Unamortized debt discount	(146,769		)	—
	Net carrying amount of 2020 Notes	$	485,731		$	—
	We entered into 2020 Notes Hedges in connection with the issuance of the 2020 Notes with three counterparties (the Option Counterparties). The 2020 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we would be required to make if holders elect to convert the 2020 Notes at a time when our stock price exceeds the conversion price. However, in connection with certain events, including a merger other than our proposed merger with Tornier, the Option Counterparties have the discretion to make certain adjustments to the 2020 Note Hedges and warrant transactions, which may reduce the effectiveness of the 2020 Note Hedges or increase our obligations under the warrant transactions. The aggregate cost of the 2020 Notes Hedges was $144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 7 of the condensed consolidated financial statements for additional information regarding the 2020 Notes Hedges and the 2020 Notes Conversion Derivative.
	We also entered into warrant transactions in which we sold warrants for an aggregate of 20.5 million shares of our common stock to the Option Counterparties, subject to adjustment. The strike price of the warrants was initially $40.00 per share, which was 59% above the last reported sale price of our common stock on February 9, 2015. The warrants are net-share settled and are exercisable over the 200 trading day period beginning on May 15, 2020. The warrant transactions will have a dilutive effect to the extent that the market value per share of our common stock during such period exceeds the applicable strike price of the warrants.
	Aside from the initial payment of the $144.8 million premium to the Option Counterparties, we do not expect to be required to make any cash payments to the Option Counterparties under the 2020 Notes Hedges and expect to be entitled to receive from the Option Counterparties cash, generally equal to the amount by which the market price per share of common stock exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2020 Notes Hedges is equal to the conversion price of the 2020 Notes. Additionally, if the market value per share of our common stock exceeds the strike price on any day during the 200 trading day measurement period under the warrant transaction, we will be obligated to issue to the Option Counterparties a number of shares equal in value to one percent of the amount by which the then-current market value of one share of our common stock exceeds the then-effective strike price of each warrant, multiplied by the number of shares of common stock into which the 2020 Notes are then convertible at or following maturity. We will not receive any additional proceeds if warrants are exercised.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities
	We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value shall be recognized currently in earnings unless specific hedge accounting criteria are met.
	2017 Conversion Derivative and Notes Hedging
	On August 31, 2012, we issued the 2017 Notes. The 2017 Notes Conversion Derivative requires bifurcation from the 2017 Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2017 Notes Conversion Derivative at the time of issuance of the 2017 Notes was $48.1 million. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2017 Notes.
	We also entered into the 2017 Notes Hedges in connection with the issuance of the 2017 Notes with certain counterparties. The 2017 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2017 Notes in excess of the principal amount of converted notes if our common stock price exceeds the conversion price. The aggregate cost of the 2017 Notes Hedges was $56.2 million and was accounted for as a derivative asset in accordance with ASC Topic 815.
	On February 13, 2015, we issued $632.5 million of the 2020 Notes, which generated proceeds of approximately $613 million net of issuance costs. We used approximately $292 million of the net proceeds from this offering to repurchase and extinguish approximately $240 million aggregate principal amount of the 2017 Notes, settle the associated portion of the 2017 Notes Conversion Derivative, approximately $49 million, and to satisfy the accrued interest of $2.4 million. We also settled all of the 2017 Notes Hedges and repurchased all of the warrants associated with the 2017 Notes, generating net proceeds of approximately $10 million. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2020 Notes.
	The following table summarizes the fair value and the presentation in the condensed consolidated balance sheet (in thousands):
		Location on condensed consolidated balance sheet	March 31, 2015		31-Dec-14
	2017 Notes Hedges	Other assets	$	—	$	80,000
	2017 Notes Conversion Derivative	Other liabilities	$	13,431	$	76,000
	Neither the 2017 Notes Conversion Derivative nor the 2017 Notes Hedges qualify for hedge accounting, thus any change in the fair value of the derivatives is recognized immediately in the condensed consolidated statements of operations. The following table summarizes the gain (loss) on changes in fair value (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	2017 Notes Hedges	$	(10,236	)	$	1,000
	2017 Notes Conversion Derivative	13,417			(2,000		)
	Net gain (loss) on changes in fair value	$	3,181		$	(1,000	)
	2020 Conversion Derivative and Notes Hedging
	On February 13, 2015, we issued the 2020 Notes. The 2020 Notes Conversion Derivative requires bifurcation from the 2020 Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2020 Notes.
	We also entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with the Option Counterparties. The 2020 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2020 Notes in excess of the principal amount of converted notes if our common stock price exceeds the conversion price. The aggregate cost of the 2020 Notes Hedges was $144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815.
		Location on condensed consolidated balance sheet	March 31, 2015		31-Dec-14
	2020 Notes Hedges	Other assets	$	135,560	$	—
	2020 Notes Conversion Derivative	Other liabilities	$	136,748	$	—
	Neither the 2020 Notes Conversion Derivative nor the 2020 Notes Hedges qualify for hedge accounting, thus any change in the fair value of the derivatives is recognized immediately in the condensed consolidated statements of operations. The following table summarizes the gain (loss) on changes in fair value (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	2020 Notes Hedges	$	(9,283	)	$	—
	2020 Notes Conversion Derivative	13,036			—
	Net gain on changes in fair value	$	3,753		$	—
	Derivatives not Designated as Hedging Instruments
	We employ a derivative program using 30-day foreign currency forward contracts to mitigate the risk of currency fluctuations on our intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts are expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts are not designated as hedging instruments under FASB ASC Topic 815. Accordingly, the changes in the fair value and the settlement of the contracts are recognized in the period incurred in the accompanying condensed consolidated statements of operations. At March 31, 2015, we had no foreign currency contracts outstanding.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible	Goodwill and Intangible Assets
	Changes in the carrying amount of goodwill occurring during the three months ended March 31, 2015, are as follows (in thousands):
		U.S.			International			BioMimetic			Total
	Goodwill at December 31, 2014	$	173,589		$	16,041		$	1,336		$	190,966
	Foreign currency translation	—			(6,242		)	—			(6,242		)
	Goodwill at March 31, 2015	$	173,589		$	9,799		$	1,336		$	184,724
	Goodwill is recognized for the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is required to be tested for impairment at least annually. Unless circumstances otherwise dictate, the annual impairment test is performed in the quarter ended December 31.
	The components of our identifiable intangible assets are as follows (in thousands):
		March 31, 2015						December 31, 2014
		Cost			Accumulated Amortization			Cost			Accumulated Amortization
	Indefinite life intangibles
	In-process research and development technology	$	4,266					$	4,266
	Tradename	3,915						4,004
	Total indefinite life intangibles	8,181						8,270
	Finite life intangibles
	Distribution channels	250			200			250			194
	Completed technology	32,496			9,982			33,253			9,185
	Licenses	8,233			1,801			8,234			1,637
	Customer relationships	26,845			5,095			27,946			4,636
	Trademarks	2,737			2,009			2,798			1,850
	Non-compete agreements	6,766			2,425			8,508			3,397
	Other	771			118			771			106
	Total finite life intangibles	78,098			$	21,630		81,760			$	21,005
	Total intangibles	86,279						90,030
	Less: Accumulated amortization	(21,630		)				(21,005		)
	Intangible assets, net	$	64,649					$	69,025
	Based on total finite life intangible assets held at March 31, 2015, we expect to amortize approximately $9.9 million for the full year of 2015, $7.5 million in 2016, $6.9 million in 2017, $5.4 million in 2018, and $4.9 million in 2019.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Accumulated Other Comprehensive Income (AOCI)
	Other comprehensive income (OCI) includes certain gains and losses that under GAAP are included in comprehensive income but are excluded from net income as these amounts are initially recorded as an adjustment to stockholders’ equity. Amounts in OCI may be reclassified to net income upon the occurrence of certain events.
	Our OCI is comprised of foreign currency translation adjustments, unrealized gains and losses on available-for-sale securities, and adjustments to our minimum pension liability. Foreign currency translation adjustments are reclassified to net income upon sale or upon a complete or substantially complete liquidation of an investment in a foreign entity. Unrealized gains and losses on available-for-sale securities are reclassified to net income if we sell the security before maturity or if the unrealized loss in a security is considered to be other-than-temporary.
	Changes in and reclassifications out of AOCI, net of tax, for the three months ended March 31, 2015 were as follows (in thousands):
		Currency Translation Adjustment (CTA)			Unrealized		Minimum		Total
					Gain(Loss) on		Pension
					Marketable Securities		Liability
							Adjustment
	Balance December 31, 2014	$	2,398		$	—	$	—	$	2,398
	Other comprehensive income (loss), net of tax	(8,997		)	—		—		(8,997		)
	Balance March 31, 2015	$	(6,599	)	$	—	$	—	$	(6,599	)

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our common stock equivalents. Our common stock equivalents consist of stock options, non-vested shares of common stock, stock-settled phantom stock units, restricted stock units, 2.625% Convertible Senior Notes maturing on December 1, 2014 (2014 Notes), and warrants. The dilutive effect of the stock options, non-vested shares of common stock, stock-settled phantom stock units, restricted stock units and warrants is calculated using the treasury-stock method. The dilutive effect of the 2014 Notes is calculated by applying the “if-converted” method. This assumes an add-back of interest, net of income taxes, to net income as if the securities were converted at the beginning of the period. During the three month period ended March 31, 2014, the 2014 Notes had an anti-dilutive effect on earnings per share and we therefore excluded them from the dilutive shares calculation. In addition, approximately 0.8 million common stock equivalents have been excluded from the computation of diluted net loss from continuing operations per share for the three month period ended March 31, 2015, because their effect is anti-dilutive as a result of our net loss in that period. In addition, approximately 1.9 million common stock equivalents have been excluded from the computation of diluted net loss from continuing operations per share for the three month period ended March 31, 2014, because their effect is anti-dilutive as a result of our net loss in that period.
	The weighted-average number of shares outstanding for basic and diluted earnings per share is as follows (in thousands):
		Three Months Ended
		March 31,
		2015	2014
	Weighted-average number of shares outstanding, basic	50,868	48,625
	Common stock equivalents	—	—
	Weighted-average number of shares outstanding, diluted	50,868	48,625
	Net-share settled warrants were anti-dilutive for the three month period ended March 31, 2015 and 2014. Additionally, the following potential common shares were excluded from common stock equivalents as their effect would have been anti-dilutive (in thousands):
		Three Months Ended
		March 31,
		2015	2014
	Stock options	1,923	159
	Non-vested shares, restricted stock units, and stock-settled phantom stock units	9	31
	2014 Notes	—	115

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Legal Contingencies
	As described below, our business is subject to various contingencies, including patent and other litigation, product liability claims and a government inquiry.  These contingencies could result in losses, including damages, fines, or penalties, any of which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and negative outcomes or verdicts can occur, we believe we have significant defenses in all of them, are vigorously defending all of them, and do not believe any of them will have a material adverse effect on our financial position. However, we could incur judgments, pay settlements, or revise our expectations regarding the outcome of any matter. Such developments, if any, could have a material adverse effect on our results of operations in the period in which applicable amounts are accrued, or on our cash flows in the period in which amounts are paid.
	Our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss or the measurement of a loss can be complex. We have accrued for losses that are both probable and reasonably estimable. Unless otherwise indicated, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued.  Our assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate. Unanticipated events and circumstances may occur that could cause us to change our estimates and assumptions.
	Governmental Inquiries
	On September 29, 2010, we entered into a five year Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the United States Department of Health and Human Services (OIG-HHS). The CIA was filed as Exhibit 10.2 to our current report on Form 8-K filed on September 30, 2010. The CIA will expire on September 29, 2015.
	The CIA imposes on us certain obligations to maintain compliance with U.S. healthcare laws, regulations and other requirements. Our failure to do so could expose us to significant liability, including, but not limited to, exclusion from federal healthcare program participation, including Medicaid and Medicare, potential prosecution, civil and criminal fines or penalties, as well as additional litigation cost and expense.
	Both we and MicroPort, who purchased our OrthoRecon business in January 2014, will continue to be subject to the CIA.
	In addition to the U.S. Attorney's Office (USAO) and OIG-HHS, other governmental agencies, including state authorities, could conduct investigations or institute proceedings that are not precluded by the CIA. In addition, the matters that gave rise to the CIA could increase our exposure to lawsuits by potential whistleblowers, including under the federal false claims acts, based on new theories or allegations arising from these matters.
	On August 3, 2012, we received a subpoena from the USAO for the Western District of Tennessee requesting records and documentation relating to our PROFEMUR® series of hip replacement devices. The subpoena covers the period from January 1, 2000 to August 2, 2012. We continue to respond to the subpoena.
	Patent Litigation
	In 2011, Howmedica Osteonics Corp. and Stryker Ireland, Ltd. (collectively, “Stryker”), each a subsidiary of Stryker Corporation, filed a lawsuit against Wright Medical Technology, Inc. (WMT) in the United States District Court for the District of New Jersey alleging that we infringed Stryker's U.S. Patent No. 6,475,243 related to our LINEAGE® Acetabular Cup System and DYNASTY® Acetabular Cup System. The lawsuit seeks an order of infringement, injunctive relief, unspecified damages, and various other costs and relief. On July 9, 2013, the Court issued a claim construction ruling. On November 25, 2014, the Court entered judgment of non-infringement in our favor. On January 7, 2015, Howmedica and Stryker filed a notice of appeal to the Court of Appeals for the Federal Circuit.
	In 2012, Bonutti Skeletal Innovations, LLC (Bonutti) filed a patent infringement lawsuit against us in the United States Court for the District of Delaware. Subsequently, Inter Partes Review (IPR) of the Bonutti patents was sought before the U.S. Patent and Trademark Office. On April 7, 2014, the Court stayed the case pending outcome of the IPR. Bonutti originally alleged that the Link Sled Prosthesis infringes U.S. Patent 6,702,821. The Link Sled Prosthesis is a product we distributed under a distribution agreement with LinkBio Corp, which expired on December 31, 2013. In January 2013, Bonutti amended its complaint, alleging that the ADVANCE® knee system, including ODYSSEY® instrumentation, infringes U.S. Patent 8,133,229, and that the ADVANCE® knee system, including ODYSSEY® instrumentation and PROPHECY® guides, infringes U.S. Patent 7,806,896, which was issued on October 5, 2010. All of the claims of the asserted patents are directed to surgical methods for minimally invasive surgery. As a result of the arguments submitted in the IPR, Bonutti abandoned the claims subject to the IPR from U.S. Patent 8,133,229, leaving one claim from U.S. Patent 7,806,896 still pending before the Patent Office Board that administers IPR’s. On February 18, 2015, the Patent Office Board held that remaining claim invalid.
	In June 2013, Orthophoenix, LLC filed a patent lawsuit against us in the United States District Court for the District of Delaware alleging that the X-REAM® product infringes two patents. In June 2014, we filed a request for IPR with the U.S. Patent and Trademark Office. In October 2014, the Court stayed the case pending outcome of the IPR. On December 16, 2014, the Patent Office Board denied our petitions requesting IPR. As a result, the District Court will lift the stay, and we will continue with our defense.
	In June 2013, Anglefix, LLC filed suit in the United States District Court for the Western District of Tennessee, alleging that our ORTHOLOC® products infringe Anglefix’s asserted patent. On April 14, 2014, we filed a request for IPR with the U.S. Patent and Trademark Office. In October 2014, the Court stayed the case pending outcome of the IPR.
	In September 2013, ConforMIS, Inc. filed suit against us in the United States District Court for the District of Massachusetts, alleging that our PROPHECY® knee and ankle systems infringe four ConforMIS’ patents. On February 19, 2014, ConforMIS filed an amended complaint asserting four additional patents against us relating to alleged infringement by our PROPHECY® knee and ankle systems and naming MicroPort Orthopedics as an additional defendant. On October 9, 2014, the parties jointly advised the Court that they had reached an agreement in principle to settle the matter. In connection with the reported settlement, we recorded expenses of $0.9 million in continuing operations and $13.8 million in discontinued operations. In addition we recorded a $4.6 million asset in connection with the fully paid non-exclusive foot and ankle license as part of the reported settlement. $10.7 million of the $13.8 million recorded in discontinued operations reflects estimated royalty payments based on future sales by MicroPort Orthopedics, which will be paid through 2026. During April 2015, final license agreements were executed and the litigation has been dismissed with prejudice.
	In February 2014, Biomedical Enterprises, Inc. filed suit against Solana Surgical, LLC in the United States District Court for the Western District of Texas alleging Solana's FuseForce Fixation system infringes U.S. Patent No. 8,584,853 entitled “Method and Apparatus for an Orthopedic Fixation System.” On February 20, 2015, we filed a request for IPR with the U.S. Patent and Trademark Office. On February 27, 2015, Biomedical Enterprises filed an amended complaint to add us and WMT as parties to the litigation. On April 3, 2015, the parties filed a stipulation of dismissal without prejudice as to us.
	On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the U.S. District Court in Minnesota, alleging that Wright’s X-REAM® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE REAMER.”  In January 2015, as the deadline for service of its complaint, Spineology dismissed its complaint without prejudice and filed a new, identical complaint. We filed an answer to the new complaint with the court on April 27, 2015.
	On January 13, 2015, we received a notice from Corin Limited claiming a portion of the INFINITY® Total Ankle System infringes their patent rights in France, Germany, Italy, Spain, the Netherlands, and the United Kingdom. We are currently investigating the merits of this claim.
	On April 17, 2015, Dr. Rama E. Chandran filed a patent infringement lawsuit against WMT in the United States District Court for the Central District of California, alleging that the Valor® Hindfoot Fusion System infringes U.S. Patent No. 6,579,293, entitled “INTRAMEDULLARY ROD WITH INTERLOCKING OBLIQUE SCREW FOR TIBIO-CALCANEAL ARTHRODESIS.” Plaintiff has not yet served the complaint.
	Subject to the provisions of the asset purchase agreement with MicroPort for the sale of our OrthoRecon business, we will continue to be responsible for defense of pre-existing patent infringement cases relating to our OrthoRecon business, and for resulting liabilities, if any.
	Product Liability
	We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular neck product (PROFEMUR® Claims). The overall fracture rate for the product is low and the fractures appear, at least in part, to relate to patient demographics. Beginning in 2009, we began offering a cobalt-chrome version of our PROFEMUR® modular neck, which has greater strength characteristics than the alternative titanium version. Historically, we have reflected our liability for these claims as part of our standard product liability accruals on a case-by-case basis. However, during the quarter ended September 30, 2011, as a result of an increase in the number and monetary amount of these claims, management estimated our liability to patients in North America who have previously required a revision following a fracture of a PROFEMUR® long titanium modular neck, or who may require a revision in the future. Management has estimated that this aggregate liability ranges from approximately $15 million to $25 million. Any claims associated with this product outside of North America, or for any other products, will be managed as part of our standard product liability accruals.
	Due to the uncertainty within our aggregate range of loss resulting from the estimation of the number of claims and related monetary payments, we have recorded a liability of $15 million, which represents the low-end of our estimated aggregate range of loss. We have classified $6 million of this liability as current in “Accrued expenses and other current liabilities” and $9 million as non-current in “Other liabilities” on our consolidated balance sheet. We expect to pay the majority of these claims within the next three years.
	We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended March 31, 2013, we received a customary reservation of rights from our primary product liability insurance carrier asserting that present and future claims related to fractures of our PROFEMUR® titanium modular neck hip products and which allege certain types of injury (Modular Neck Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place Modular Neck Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees with the assertion that the Modular Neck Claims should be treated as a single occurrence, but notified the carrier that it disputed the carrier's selection of available policy years. During the second quarter of 2013, we received confirmation from the primary carrier confirming their agreement with our policy year determination. Based on our insurer's treatment of Modular Neck Claims as a single occurrence, we increased our estimate of the total probable insurance recovery related to Modular Neck Claims by $19.4 million, and recognized such additional recovery as a reduction to our selling, general and administrative expenses for the three-months ended March 31, 2013, within results of discontinued operations. In the quarter ended June 30, 2013, we received payment from the primary insurance carrier of $5 million. In the quarter ended September 30, 2013, we received payment of $10 million from the next insurance carrier in the tower. As of March 31, 2015, our insurance receivable related to Modular Neck Claims totals $25 million, which consists of $25 million for cash spending to date associated with defense and settlement costs. We have classified $25 million within current receivables. We have requested, but not yet received, payment of this amount from the third insurance carrier in the tower for that policy period. That carrier has continued to seek information related to the Modular Neck Claims in order to complete its investigation, and has reserved its rights with respect to a number of terms and conditions in its policy that could limit or preclude coverage. We have responded to those requests. While we expect the excess carrier ultimately will adopt the coverage position taken by the two underlying carriers, it is possible it will assert that the terms and conditions identified in its reservation of rights will preclude coverage for the Modular Neck Claims. If that were to occur, we would dispute that position and seek recourse in the appropriate forum.
	During the quarter ended September 30, 2013, we reached the maximum insurance coverage for Modular Neck Claims of $40 million, when previous spending on legal defense costs and claim settlements are combined with our estimated product liability for future settlements. As a result, we recognized approximately $2.7 million of expense within results from discontinued operations for 2015 for legal expenses and adjustments to our estimated liabilities for future settlements recognized in excess of the $40 million insurance recovery limit. Future expenses associated with defense costs and revisions to our estimated product liability will be recognized as incurred within results of discontinued operations. As noted above, our insurance receivable for cash spending is $25 million, and all remaining cash spending will be in excess of this maximum.
	Claims for personal injury have also been made against us associated with our metal-on-metal hip products (primarily our CONSERVE® product line). The pre-trial management of certain of these claims has been consolidated in the federal court system under multi-district litigation, and certain other claims in state courts in California, collectively the “Consolidated Metal-on-Metal Claims,” as further discussed in Part II Item I of this Quarterly Report. The number of these lawsuits presently exceeds 1,000. We have also entered into an excess of 700 so called "tolling agreements" with potential claimants who have not yet filed suit. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products. While continuing to dispute liability, we are participating in court supervised non-binding mediation in the multi-district federal court litigation. This mediation is continuing. The supervising judge in the Federal Court consolidated proceedings has advised the parties that he may set a bellwether trial date in August or September 2015, and the supervising judge in the California state court proceeding has set a trial date in March 2016.
	We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended September 30, 2012, we received a customary reservation of rights from our primary product liability insurance carrier asserting that certain present and future claims which allege certain types of injury related to our CONSERVE® metal-on-metal hip products (CONSERVE® Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place CONSERVE® Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees that there is insurance coverage for the CONSERVE® Claims, but has notified the carrier that it disputes the carrier's characterization of the CONSERVE® Claims as a single occurrence.
	Management has recorded an insurance receivable for the probable recovery of spending in excess of our retention for a single occurrence. During the first quarter of 2015, we received $5 million of insurance proceeds, which represent the amount undisputed by the carrier for the policy year the first claim was asserted. Our acceptance of these proceeds was not a waiver of any other claim that we may have against the insurance carrier. As of March 31, 2015, this receivable totaled $10.9 million, and is solely related to defense costs incurred through March 31, 2015. However, the amount we ultimately receive may differ depending on the final conclusion of the insurance policy year or years and the number of occurrences. We believe our contracts with the insurance carriers are enforceable for these claims and, therefore, we believe it is probable that we will receive recoveries from our insurance carriers. However, our insurance carriers could still ultimately deny coverage for some or all of our insurance claims.
	Every metal-on-metal hip case involves fundamental issues of science and medicine that often are uncertain, that continue to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and issues include medical causation, individual patient characteristics, surgery specific factors, and the existence of actual, provable injury. Given these complexities, we do not believe a loss is probable. Although we continue to contest liability, based upon currently available information, we estimate a reasonably possible range of liability for the Consolidated Metal-on-Metal Claims, before insurance recoveries, averaging from zero to $250,000 per case.
	Based upon the information we have at this time, we do not believe our liabilities, if any, in connection with these matters will exceed our available insurance. However, as described below, we are currently litigating coverage issues with certain of our carriers. As the litigation moves forward and circumstances continue to develop, our belief we will be able to resolve the Consolidated Metal-on-Metal Claims within available insurance coverage could change, which could materially impact our results of operations and financial position. Further, and notwithstanding our present belief we will be able to resolve these Claims within available insurance proceeds, we would consider contributing a limited amount to the funding of an acceptable, comprehensive, mediated settlement among claimants and insurers. To this end, we have indicated a willingness to contribute up to $30 million to achieve such a comprehensive settlement. Due to continuing uncertainty around (i) whether a multi-party comprehensive settlement can be achieved, (ii) the outcome of our coverage litigation with insurers which could impact the ability to reach a settlement and (iii) the case by case outcomes of any Metal-on-Metal claims ultimately litigated (and which we expect to contest vigorously), we do not believe a loss is probable and, therefore, no amounts have been accrued.
	In June 2014, St. Paul Surplus Lines Insurance Company (“Travelers”), which was an excess carrier in our coverage towers across multiple policy years, filed a declaratory judgment action in Tennessee state court naming us and certain of our other insurance carriers as defendants and asking the court to rule on the rights and responsibilities of the parties with regard to the CONSERVE® Claims. Among other things, Travelers appears to dispute our contention that the CONSERVE® Claims arise out of more than a single occurrence thereby triggering multiple policy periods of coverage.  Travelers further seeks a determination as to the applicable policy period triggered by the alleged single occurrence.  We filed a separate lawsuit in state court in California for declaratory judgment against certain carriers and breach of contract against the primary carrier, and have moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate jurisdiction. During the third quarter of 2014, the California Court granted Travelers' motion to stay our California action.
	In February 2014, Biomet, Inc. (Biomet) announced it had reached a settlement in the multi-district litigation involving its own metal-on-metal hip products. The terms announced by Biomet include: (i) an expected base settlement amount of $200,000; (ii) an expected minimum settlement amount of $20,000; (iii) no payments to plaintiffs who did not undergo a revision surgery; and (iv) a total settlement amount expected to be within Biomet’s aggregate insurance coverage. We believe our situation involves facts and circumstances that differ significantly from the Biomet cases.
	In addition to the Consolidated Metal-on-Metal Claims discussed above, there are currently certain other pending claims related to our metal-on-metal hip products for which we are accounting in accordance with our standard product liability accrual methodology on a case by case basis.
	Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee products sold prior to the closing, were not assumed by MicroPort. Liabilities associated with these product liability claims, including legal defense, settlements and judgments, income associated with product liability insurance recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results of discontinued operations, and we will continue to reflect these within results of discontinued operations in future periods. MicroPort is responsible for product liability claims associated with products it sells after the closing.
	Employment Litigation
	In 2012, two former employees, Frank Bono and Alicia Napoli, each filed separate lawsuits against WMT in the Chancery Court of Shelby County, Tennessee, which asserted claims for retaliatory discharge and breach of contract based upon his or her respective separation pay agreement. In addition, Mr. Bono and Ms. Napoli each asserted a claim for defamation related to the press release issued at the time of their terminations and a wrongful discharge claim alleging violation of the Tennessee Public Protection Act. Mr. Bono and Ms. Napoli each claimed that he or she was entitled to attorney fees in addition to other unspecified damages. On October 23, 2013, Ms. Napoli moved to voluntary dismiss her lawsuit, without prejudice. On April 4, 2014, Ms. Napoli refiled her case in the United States District Court for the Eastern District of Missouri. In July 2014, we were successful in having the case that was refiled in Missouri transferred to the U.S. District Court for the Western District of Tennessee.
	Other
	In addition to those noted above, we are subject to various other legal proceedings, product liability claims, corporate governance, and other matters which arise in the ordinary course of business.

Segment_Information_Notes

Segment Information (Notes)	3 Months Ended
	Mar. 31, 2015
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment Reporting Disclosure [Text Block]	Segment Information
	During the first quarter of 2014, our management, including our chief executive officer, who is our chief operating decision maker, began managing our operations as three operating business segments: U.S., International and BioMimetic, based on management's change to the way it monitors performance, aligns strategies, and allocates resources results in a change in our reportable segments. We determined that each of these operating segments represented a reportable segment.
	Our U.S. and International segments represent the commercial, administrative and research & development activities dedicated to the respective geographies. The BioMimetic segment represents the administrative and research & development activities of the acquired BioMimetic business (international sales and associated expenses for Augment® products are included within the International segment). The Corporate category shown in the table below primarily reflects general and administrative expenses not specifically associated with the U.S., International or BioMimetic segments. These non-allocated corporate expenses relate to global administrative expenses that support all segments, including salaries and benefits of executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all stock-based compensation.
	Management measures segment profitability using an internal operating performance measure that excludes the impact of inventory step-up amortization, charges associated with distributor conversions and related non-competes, and due diligence, transaction and transition costs associated with acquisitions.
	Selected financial information related to our segments is presented below for the three-months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended March 31, 2015
		U.S.		International			BioMimetic			Corporate			Total
	Sales	$	57,486	$	20,448		$	—		$	—		$	77,934
	Depreciation expense	3,020		768			37			1,455			5,280
	Amortization expense	2,059		470			61			—			2,590
	Segment operating income (loss)	$	2,371	$	(3,125	)	$	(3,244	)	$	(18,047	)	$	(22,045	)
	Other:
	Inventory step-up amortization												(28		)
	Distributor conversion and non-compete charges												(24		)
	Due diligence, transaction and transition expenses												(11,024		)
	Operating loss												(33,121		)
	Interest expense, net												7,649
	Other (income) expense, net												5,312
	Loss before income taxes												$	(46,082	)
	Capital expenditures	$	10,746	$	1,055		$	28		$	25		$	11,854
		Three Months Ended March 31, 2014
		U.S.		International			BioMimetic			Corporate			Total
	Sales	$	48,951	$	22,111		$	—		$	—		$	71,062
	Depreciation expense	2,297		641			108			1,195			4,241
	Amortization expense	1,096		577			77			—			1,750
	Segment operating income (loss)	$	5,679	$	803		$	(3,391	)	$	(17,589	)	$	(14,498	)
	Other:
	Inventory step-up amortization												(604		)
	Distributor conversion and non-compete charges												(542		)
	Due diligence, transaction and transition expenses												(7,402		)
	Operating loss												(23,046		)
	Interest expense, net												$	4,136
	Other (income) expense, net												$	15,286
	Loss before income taxes												$	(42,468	)
	Capital expenditures	$	5,200	$	733		$	2		$	1,901		$	7,836
	Assets in the U.S., International and BioMimetic segments are those assets used exclusively in the operations of each business segment or allocated when used jointly. Assets in the Corporate category are principally cash and cash equivalents, marketable securities, derivative asset, property, plant and equipment associated with our corporate headquarters, assets associated with OrthoRecon insurance receivables, and assets associated with income taxes. Total assets by business segment as of March 31, 2015 and December 31, 2014 are as follows (in thousands):
		31-Mar-15
		U.S.		International			BioMimetic			Corporate			Total
	Total assets	$	449,283	$	98,425		$	19,885		$	633,715		$	1,201,308
		31-Dec-14
		U.S.		International			BioMimetic			Corporate			Total
	Total assets	$	450,055	$	94,412		$	17,924		$	330,285		$	892,676
	Our principal geographic regions consist of the United States, Europe (which includes the Middle East and Africa), and Other (which principally represents Asia, Australia, Canada, and Latin America). The following table presents net sales by geographic area for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended
	Geographic	31-Mar-15			31-Mar-14				% change
	United States	$	57,486		$	48,951			17.4	%
	Europe	12,248			13,742				(10.9	%)
	Other	8,200			8,369				(2.0	%)
	Total net sales	$	77,934		$	71,062			9.7	%

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group, Inc. have been prepared in accordance with accounting principles generally accepted (GAAP) in the United States (U.S.) for interim financial statements and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2015.
	In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year. Certain prior year amounts have been reclassified to conform with the current year presentation, including amounts related to discontinued operations.
	The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our domestic and international subsidiaries, all of which are wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
	The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the dates of the financial statements and the amounts of revenues and expenses during the reporting periods. Actual amounts realized or paid could differ from those estimates.

Earnings_Per_Share_Policies

Earnings Per Share (Policies)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share, FASB ASC Topic 260	FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our common stock equivalents. Our common stock equivalents consist of stock options, non-vested shares of common stock, stock-settled phantom stock units, restricted stock units, 2.625% Convertible Senior Notes maturing on December 1, 2014 (2014 Notes), and warrants. The dilutive effect of the stock options, non-vested shares of common stock, stock-settled phantom stock units, restricted stock units and warrants is calculated using the treasury-stock method. The dilutive effect of the 2014 Notes is calculated by applying the “if-converted” method. This assumes an add-back of interest, net of income taxes, to net income as if the securities were converted at the beginning of the period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Credit Risk Assumptions for Derivatives [Table Text Block]	The following assumptions were used in the fair market valuations of the 2017 Notes Conversion Derivative and 2020 Notes Conversion Derivative and 2020 Notes Hedges as of March 31, 2015:
		2017 Notes Conversion Derivative		2020 Notes Conversion Derivative		2020 Notes Hedge
	Stock Price Volatility (1)	35	%	35	%	35	%
	Credit Spread for Wright (2)	4.9	%	4.5	%	4.5	%
	Credit Spread for Deutsche Bank AG (3)	N/A		N/A		0.8	%
	Credit Spread for Wells Fargo Securities, LLC (3)	N/A		N/A		0.6	%
Valuation of Financial Instruments at Fair Value Table	The following table summarizes the valuation of our financial instruments measured at fair value on a recurring basis (in thousands):
		Total			Quoted Prices			Prices with			Prices with
					in Active			Other			Unobservable
					Markets			Observable			Inputs
					(Level 1)			Inputs			(Level 3)
								(Level 2)
	At March 31, 2015
	Assets
	Cash and cash equivalents	$	465,249		$	465,249		$	—		$	—
	Available-for-sale marketable securities
	Corporate debt securities	—			—			—			—
	U.S. government debt securities	—			—			—			—
	Total available-for-sale marketable securities	—			—			—			—
	2020 Notes Hedges	135,560			—			—			135,560
	Total	$	600,809		$	465,249		$	—		$	135,560
	Liabilities
	2017 Notes Conversion Derivative	$	13,431		$	—		$	—		$	13,431
	2020 Notes Conversion Derivative	136,748			—			—			136,748
	Contingent consideration	1,632			—						1,632
	Contingent consideration (CVR)	120,527			120,527			—			—
	Total	$	272,338		$	120,527		$	—		$	151,811
		Total			Quoted Prices			Prices with			Prices with
					in Active			Other			Unobservable
					Markets			Observable			Inputs
					(Level 1)			Inputs			(Level 3)
								(Level 2)
	At December 31, 2014
	Assets
	Cash and cash equivalents	$	227,326		$	227,326		$	—		$	—
	Available-for-sale marketable securities
	Corporate debt securities	566			—			566			—
	U.S. Government debt securities	2,009			2,009			—			—
	Total available-for-sale marketable securities	2,575			2,009			566			—
	2017 Notes Hedges	80,000			—			—			80,000
	Total	$	309,901		$	229,335		$	566		$	80,000
	Liabilities
	2017 Notes Conversion Derivative	$	76,000		$	—		$	—		$	76,000
	Contingent consideration	1,705			—			—			1,705
	Contingent consideration (CVR)	$	133,981		133,981			$	—		$	—
	Total	$	211,686		$	133,981		$	—		$	77,705
Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation	The following is a roll forward of our assets and liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3):
			Balance at December 31, 2014			Transfers into Level 3		Gain/(Losses) included in Earnings		Currency		Settlements		Balance at March 31, 2015
	2017 Notes Hedges		$	80,000		—		(10,236	)	—		(69,764	)	$	—
	2017 Notes Conversion Derivative		$	(76,000	)	—		13,417		—		49,152		$	(13,431	)
	2020 Notes Hedges		$	—		144,843		(9,283	)	—		—		$	135,560
	2020 Notes Conversion Derivative		$	—		(149,784	)	13,036		—		—		$	(136,748	)
	Contingent Consideration		$	(1,705	)	—		—		73		—		$	(1,632	)

Discontinued_Operations_Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
		Three Months Ended
		March 31,
		2015			2014
	Revenue	$	—		$	2,942
	(Loss) income before tax (including $24.3 million gain from disposal in 2014)	(3,500		)	15,334
	Income tax (benefit) provision	—			15,456
	(Loss) income from discontinued operations, net of tax	(3,500		)	(122		)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	8,435	$	6,910
	Work-in-process	20,216		13,849
	Finished goods	73,225		67,653
		$	101,876	$	88,412

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2015
Marketable Securities [Abstract]
Summary of Marketable Securities Table	The following tables present a summary of our marketable securities as of December 31, 2014 (in thousands):
		Amortized Cost		Gross		Gross		Estimated
				Unrealized		Unrealized		Fair Value
				Gains		(Losses)
	At December 31, 2014
	Available-for-sale marketable securities
	Corporate debt securities	566		—		—		566
	U.S. government debt securities	2,009		—		—		2,009
	Total available-for-sale marketable securities	$	2,575	$	—	$	—	$	2,575

Property_Plant_and_Equipment_N1

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Property, plant and equipment, at cost	$	199,599		$	191,094
	Less: Accumulated depreciation	(90,747		)	(86,859		)
		$	108,852		$	104,235

LongTerm_Debt_and_Capital_Leas1

Long-Term Debt and Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2015
Long-term Debt and Capital Lease Obligations [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt and capital lease obligations consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Capital lease obligations	$	8,492		$	8,678
	2017 Notes	55,012			272,652
	2020 Notes	485,731			—
		549,235			281,330
	Less: current portion	(733		)	(718		)
		$	548,502		$	280,612
Components of Convertible Debt
		31-Mar-15			31-Dec-14
	Principal amount of 2020 Notes	$	632,500		$	—
	Unamortized debt discount	(146,769		)	—
	Net carrying amount of 2020 Notes	$	485,731		$	—

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)	3 Months Ended
	Mar. 31, 2015
2017 Derivatives [Member] [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Fair Value	Neither the 2017 Notes Conversion Derivative nor the 2017 Notes Hedges qualify for hedge accounting, thus any change in the fair value of the derivatives is recognized immediately in the condensed consolidated statements of operations. The following table summarizes the gain (loss) on changes in fair value (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	2017 Notes Hedges	$	(10,236	)	$	1,000
	2017 Notes Conversion Derivative	13,417			(2,000		)
	Net gain (loss) on changes in fair value	$	3,181		$	(1,000	)
Summary of fair value and the presentation in the consolidated balance sheet	The following table summarizes the fair value and the presentation in the condensed consolidated balance sheet (in thousands):
		Location on condensed consolidated balance sheet	March 31, 2015		31-Dec-14
	2017 Notes Hedges	Other assets	$	—	$	80,000
	2017 Notes Conversion Derivative	Other liabilities	$	13,431	$	76,000
2020 Derivatives [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Fair Value
		Three Months Ended
		March 31,
		2015			2014
	2020 Notes Hedges	$	(9,283	)	$	—
	2020 Notes Conversion Derivative	13,036			—
	Net gain on changes in fair value	$	3,753		$	—
Summary of fair value and the presentation in the consolidated balance sheet
		Location on condensed consolidated balance sheet	March 31, 2015		31-Dec-14
	2020 Notes Hedges	Other assets	$	135,560	$	—
	2020 Notes Conversion Derivative	Other liabilities	$	136,748	$	—

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill Table	Changes in the carrying amount of goodwill occurring during the three months ended March 31, 2015, are as follows (in thousands):
		U.S.			International			BioMimetic			Total
	Goodwill at December 31, 2014	$	173,589		$	16,041		$	1,336		$	190,966
	Foreign currency translation	—			(6,242		)	—			(6,242		)
	Goodwill at March 31, 2015	$	173,589		$	9,799		$	1,336		$	184,724
Components of Identifiable Assets Table	The components of our identifiable intangible assets are as follows (in thousands):
		March 31, 2015						December 31, 2014
		Cost			Accumulated Amortization			Cost			Accumulated Amortization
	Indefinite life intangibles
	In-process research and development technology	$	4,266					$	4,266
	Tradename	3,915						4,004
	Total indefinite life intangibles	8,181						8,270
	Finite life intangibles
	Distribution channels	250			200			250			194
	Completed technology	32,496			9,982			33,253			9,185
	Licenses	8,233			1,801			8,234			1,637
	Customer relationships	26,845			5,095			27,946			4,636
	Trademarks	2,737			2,009			2,798			1,850
	Non-compete agreements	6,766			2,425			8,508			3,397
	Other	771			118			771			106
	Total finite life intangibles	78,098			$	21,630		81,760			$	21,005
	Total intangibles	86,279						90,030
	Less: Accumulated amortization	(21,630		)				(21,005		)
	Intangible assets, net	$	64,649					$	69,025

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2015
Accumulated Other Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in and reclassifications out of AOCI, net of tax, for the three months ended March 31, 2015 were as follows (in thousands):
		Currency Translation Adjustment (CTA)			Unrealized		Minimum		Total
					Gain(Loss) on		Pension
					Marketable Securities		Liability
							Adjustment
	Balance December 31, 2014	$	2,398		$	—	$	—	$	2,398
	Other comprehensive income (loss), net of tax	(8,997		)	—		—		(8,997		)
	Balance March 31, 2015	$	(6,599	)	$	—	$	—	$	(6,599	)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Weighted average number of shares outstanding for basic and diluted earnings per share	The weighted-average number of shares outstanding for basic and diluted earnings per share is as follows (in thousands):
		Three Months Ended
		March 31,
		2015	2014
	Weighted-average number of shares outstanding, basic	50,868	48,625
	Common stock equivalents	—	—
	Weighted-average number of shares outstanding, diluted	50,868	48,625
Antidilutive potential common shares resulting from reasons other than net loss incurred excluded from the diluted earnings per share computation	he following potential common shares were excluded from common stock equivalents as their effect would have been anti-dilutive (in thousands):
		Three Months Ended
		March 31,
		2015	2014
	Stock options	1,923	159
	Non-vested shares, restricted stock units, and stock-settled phantom stock units	9	31
	2014 Notes	—	115

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Total assets by business segment as of March 31, 2015 and December 31, 2014 are as follows (in thousands):
		31-Mar-15
		U.S.		International			BioMimetic			Corporate			Total
	Total assets	$	449,283	$	98,425		$	19,885		$	633,715		$	1,201,308
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Selected financial information related to our segments is presented below for the three-months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended March 31, 2015
		U.S.		International			BioMimetic			Corporate			Total
	Sales	$	57,486	$	20,448		$	—		$	—		$	77,934
	Depreciation expense	3,020		768			37			1,455			5,280
	Amortization expense	2,059		470			61			—			2,590
	Segment operating income (loss)	$	2,371	$	(3,125	)	$	(3,244	)	$	(18,047	)	$	(22,045	)
	Other:
	Inventory step-up amortization												(28		)
	Distributor conversion and non-compete charges												(24		)
	Due diligence, transaction and transition expenses												(11,024		)
	Operating loss												(33,121		)
	Interest expense, net												7,649
	Other (income) expense, net												5,312
	Loss before income taxes												$	(46,082	)
	Capital expenditures	$	10,746	$	1,055		$	28		$	25		$	11,854
		Three Months Ended March 31, 2014
		U.S.		International			BioMimetic			Corporate			Total
	Sales	$	48,951	$	22,111		$	—		$	—		$	71,062
	Depreciation expense	2,297		641			108			1,195			4,241
	Amortization expense	1,096		577			77			—			1,750
	Segment operating income (loss)	$	5,679	$	803		$	(3,391	)	$	(17,589	)	$	(14,498	)
	Other:
	Inventory step-up amortization												(604		)
	Distributor conversion and non-compete charges												(542		)
	Due diligence, transaction and transition expenses												(7,402		)
	Operating loss												(23,046		)
	Interest expense, net												$	4,136
	Other (income) expense, net												$	15,286
	Loss before income taxes												$	(42,468	)
	Capital expenditures	$	5,200	$	733		$	2		$	1,901		$	7,836
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	The following table presents net sales by geographic area for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended
	Geographic	31-Mar-15			31-Mar-14				% change
	United States	$	57,486		$	48,951			17.4	%
	Europe	12,248			13,742				(10.9	%)
	Other	8,200			8,369				(2.0	%)
	Total net sales	$	77,934		$	71,062			9.7	%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended	3 Months Ended
	Feb. 13, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 01, 2013	Dec. 31, 2014	Aug. 22, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Repayments of Debt	$292,000,000
Mark-to-market adjustment for CVRs (Note 1)		-13,454,000	14,295,000
Acquisitions Prior to 2012 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		200,000
WG Healthcare [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		1,400,000
BioMimetics [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value				6.5
2020convertibledebt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, gross	632,500,000
Convertible senior notes		664,500,000
2020convertibledebt [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, gross	632,500,000
2017convertibledebt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, gross		60,000,000			300,000,000	300,000,000
Repayments of Debt		240,000,000
Stated percentage rate						2.00%
Convertible senior notes		69,400,000
2017convertibledebt [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, gross		60,000,000
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		1,632,000			1,705,000
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		0			0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value					0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		1,632,000			1,705,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		120,527,000			133,981,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		120,527,000			133,981,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		0			0
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent Consideration Fair Value		$0			$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Valuation of Financial Instruments (Details) (USD $)	0 Months Ended	3 Months Ended
	Feb. 13, 2015	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayments of Debt	$292,000,000
Fair Value, Measurements, Recurring [Member]
Assets
Cash and cash equivalents		465,249,000	227,326,000
Total Available For Sale Securities		0	2,575,000
Total Assets		600,809,000	309,901,000
Liabilities
Total Liabilities		272,338,000	211,686,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Cash and cash equivalents		465,249,000	227,326,000
Total Available For Sale Securities		0	2,009,000
Notes Hedges		0	0
Total Assets		465,249,000	229,335,000
Liabilities
Total Liabilities		120,527,000	133,981,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Cash and cash equivalents		0	0
Total Available For Sale Securities		0	566,000
Notes Hedges		0	0
Total Assets		0	566,000
Liabilities
Total Liabilities		0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Cash and cash equivalents		0	0
Total Available For Sale Securities		0	0
Total Assets		135,560,000	80,000,000
Liabilities
Total Liabilities		151,811,000	77,705,000
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities
Contingent Consideration Fair Value		1,632,000	1,705,000
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities
Contingent Consideration Fair Value		0	0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities
Contingent Consideration Fair Value			0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities
Contingent Consideration Fair Value		1,632,000	1,705,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities
Contingent Consideration Fair Value		120,527,000	133,981,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities
Contingent Consideration Fair Value		120,527,000	133,981,000
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities
Contingent Consideration Fair Value		0	0
ContingentValueRights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities
Contingent Consideration Fair Value		0	0
US Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Estimated Fair Value		0	2,009,000
US Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Estimated Fair Value		0	2,009,000
US Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Estimated Fair Value		0	0
US Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Estimated Fair Value		0	0
Corporate debt securities [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Estimated Fair Value		0	566,000
Corporate debt securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Estimated Fair Value		0	0
Corporate debt securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Estimated Fair Value		0	566,000
Corporate debt securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Estimated Fair Value		0	0
2017 Notes Hedges [Member]
Assets
Notes Hedges		0	80,000,000
Liabilities
Notes Conversion Derivative		13,431,000	76,000,000
2017 Notes Hedges [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Notes Hedges			80,000,000
2020 Notes Hedges [Member]
Assets
Notes Hedges		135,560,000
2020 Notes Hedges [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Notes Hedges		135,560,000
2017 Notes Conversion Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayments of Debt		240,000,000
2017 Notes Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities
Notes Conversion Derivative		13,431,000	76,000,000
2017 Notes Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities
Notes Conversion Derivative		0	0
2017 Notes Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities
Notes Conversion Derivative		0	0
2017 Notes Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities
Notes Conversion Derivative		13,431,000	76,000,000
2020 Conversion Derivative [Member]
Liabilities
Notes Conversion Derivative		136,748,000
2020 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities
Notes Conversion Derivative		136,748,000
2020 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities
Notes Conversion Derivative		0
2020 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities
Notes Conversion Derivative		0
2020 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities
Notes Conversion Derivative		136,748,000
2017convertibledebt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayments of Debt		$240,000,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies Summary of Significant Accounting Policies Fair Value Measurments (Assets and Liabilities Measured At Fair Value on A Recurring Basis Using Unobservable Inputs (Level 3) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Mark-to-market adjustment for CVRs (Note 1)	($13,454,000)	$14,295,000
2020 Conversion Derivative [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	-136,748,000		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	-149,784,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	13,036,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	0
Contingent Consideration [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	-1,632,000		-1,705,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency	73,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	0
2017 Notes Conversion Derivative [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	-13,431,000		-76,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	13,417,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	49,152,000
2020 Notes Hedges [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	135,560,000		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3	144,843,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	-9,283,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency	0
2017 Notes Hedges [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	0		80,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	-10,236,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements	-69,764,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency	$0
2020 Conversion Derivative [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Assumptions, Expected Volatility Rate	35.00%
2020 Conversion Derivative [Member] | Wright Medical Group, Inc. [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Inputs, Entity Credit Risk	4.50%
2017 Notes Conversion Derivative [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Assumptions, Expected Volatility Rate	35.00%
2017 Notes Conversion Derivative [Member] | Wright Medical Group, Inc. [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Inputs, Entity Credit Risk	4.90%
2020 Notes Hedges [Member] | Wright Medical Group, Inc. [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Assumptions, Expected Volatility Rate	35.00%
Fair Value Inputs, Entity Credit Risk	4.50%
2020 Notes Hedges [Member] | DEUTSCHE BANK ATS [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Inputs, Entity Credit Risk	0.80%
2020 Notes Hedges [Member] | WELLS FARGO LIQUIDITY CROSS ATS [Member]
FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock [Line Items]
Fair Value Inputs, Entity Credit Risk	0.60%

Acquisitions_Details

Acquisitions (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$184,724		$190,966
Net sales	$77,934	$71,062

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	0 Months Ended	3 Months Ended
	Jan. 09, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill, Written off Related to Sale of Business Unit			$25,800,000
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax		0	24,277,000
Purchase Price Discontinued Operations	283,000,000
Disposal Group, Including Discontinued Operation, Revenue		0	2,942,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax		-3,500,000	15,334,000
Discontinued Operation, Tax Effect of Discontinued Operation		0	15,456,000
(Loss) Income from Discontinued Operations, Net of Tax, Attributable to Parent		-3,500,000	-122,000
PROPHECY [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments for Legal Settlements				900,000
PROPHECY [Member] | MicroPort [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments for Legal Settlements				$13,800,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$8,435	$6,910
Work-in-process	20,216	13,849
Finished goods	73,225	67,653
Total Inventory	$101,876	$88,412

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Marketable Securities [Abstract]
Current Marketable Securities		$0	$2,575
Categories of Investments, Marketable Securities, Available-for-sale Securities [Member]
Schedule of Marketable Securities [Line Items]
Amortized Cost			2,575
Gross Unrealized Gains	0
Gross Unrealized (Losses)	0
Estimated Fair Value			2,575
Categories of Investments, Marketable Securities, Available-for-sale Securities [Member] | Corporate debt securities [Member]
Schedule of Marketable Securities [Line Items]
Amortized Cost			566
Gross Unrealized Gains	0
Gross Unrealized (Losses)	0
Estimated Fair Value			566
Categories of Investments, Marketable Securities, Available-for-sale Securities [Member] | U.S. government debt securities [Member]
Schedule of Marketable Securities [Line Items]
Amortized Cost			2,009
Gross Unrealized Gains	0
Gross Unrealized (Losses)	0
Estimated Fair Value			$2,009

Property_Plant_and_Equipment_N2

Property, Plant and Equipment, Net (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, at cost	$199,599	$191,094
Less: Accumulated depreciation	-90,747	-86,859
Net property, plant and equipment	$108,852	$104,235

LongTerm_Debt_and_Capital_Leas2

Long-Term Debt and Capital Lease Obligations (Details) (USD $)	0 Months Ended	3 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Feb. 13, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Mar. 31, 2013	Sep. 30, 2012	Aug. 22, 2012	Aug. 31, 2012
Debt and Capital Lease Obligations [Abstract]
Debt and capital lease obligations		$549,235,000		$281,330,000
Less: Current portion		-733,000		-718,000
Long term debt and capital lease obligations		548,502,000		280,612,000
Repayments of Debt	292,000,000
Payments for bond hedge options			56,200,000
Repayments of Convertible Debt		240,000,000	0
Write off of pro-rata unamortized deferred financing fees and for bank and legal fees		24,746,000	0
Amortization of Debt Discount (Premium)		1,400,000
Derivative, Cost of Hedge		-144,843,000
2017convertibledebt [Member]
Debt Instrument [Line Items]
Long-term debt, gross		60,000,000		300,000,000			300,000,000
Debt Instrument, Unamortized Discount		-4,988,000		-27,348,000
Debt and Capital Lease Obligations [Abstract]
Debt and capital lease obligations		55,012,000		272,652,000
Stated percentage rate							2.00%
Maturity date		15-Aug-17
Debt Instrument, Interest Rate, Effective Percentage					6.47%
Repayments of Debt		240,000,000
Debt instrument, convertible, conversion ratio		39.314
Conversion price (in dollars per share)		$25.44
Threshold for Conversion as Percent of Conversion Price		130.00%
Threshold for Conversion		98.00%
Debt instrument, convertible, minimum consecutive period		20 days
Debt instrument, convertible, trading period		30 days
Debt instrument, convertible, purchase Price as a Percent of principal amount if fundamental change event occurs		100.00%
Deferred finance charges						8,800,000
Capital Lease Obligations [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and capital lease obligations		8,492,000		8,678,000
2020convertibledebt [Member]
Debt Instrument [Line Items]
Long-term debt, gross	632,500,000
Debt Instrument, Unamortized Discount		-146,769,000
Debt and Capital Lease Obligations [Abstract]
Debt and capital lease obligations		485,731,000		0
Maturity date		15-Feb-20
Debt Instrument, Interest Rate, Effective Percentage		8.54%
Incremental Common Shares Attributable to Call Options and Warrants		20.5
Debt instrument, convertible, conversion ratio		32.394
Conversion price (in dollars per share)		$30.87
Threshold for Conversion as Percent of Conversion Price		130.00%
Debt instrument, convertible, minimum consecutive period		20 days
Debt instrument, convertible, trading period		30 days
Debt instrument, convertible, purchase Price as a Percent of principal amount if fundamental change event occurs		100.00%
Deferred finance charges		18,100,000
Amortization of Debt Discount (Premium)		3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$40
2017 Notes Conversion Derivative [Member]
Debt and Capital Lease Obligations [Abstract]
Repayments of Debt		240,000,000
Write off of pro-rata unamortized deferred financing fees and for bank and legal fees		24,700,000
Debt Discount at Time of Issuance								48,100,000
2020 Conversion Derivative [Member]
Debt and Capital Lease Obligations [Abstract]
Debt Discount at Time of Issuance	149,800,000
2020 Notes Hedges [Member]
Debt and Capital Lease Obligations [Abstract]
Derivative, Cost of Hedge	$144,800,000

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities (Details) (USD $)	0 Months Ended	3 Months Ended
	Feb. 13, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Aug. 31, 2012
Derivatives, Fair Value [Line Items]
Payments for bond hedge options			$56,200,000
Repayments of Debt	292,000,000
Proceedsfrom2017bondhegdessettlement	10,000,000
Non Cash Adjustment Derivative Fair Value		6,935,000	-1,000,000
Derivative, Cost of Hedge		-144,843,000
Amortization of Debt Discount (Premium)		1,400,000
2017 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Notes Hedges		0		80,000,000
Notes Conversion Derivative		13,431,000		76,000,000
Derivative, Gain (Loss) on Derivative, Net		-10,236,000	1,000,000
2017 Notes Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Debt Discount at Time of Issuance					48,100,000
Repayments of Debt		240,000,000
Derivative, Gain (Loss) on Derivative, Net		13,417,000	-2,000,000
2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Notes Hedges		135,560,000
Derivative, Gain (Loss) on Derivative, Net		-9,283,000
2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Debt Discount at Time of Issuance	149,800,000
Notes Conversion Derivative		136,748,000
Derivative, Gain (Loss) on Derivative, Net		13,036,000
2017 Change in Derivative Fair Value [Member]
Derivatives, Fair Value [Line Items]
Non Cash Adjustment Derivative Fair Value		-3,181,000	1,000,000
2020 Change in Derivative Fair Value [Member]
Derivatives, Fair Value [Line Items]
Non Cash Adjustment Derivative Fair Value		-3,753,000
2020convertibledebt [Member]
Derivatives, Fair Value [Line Items]
Proceeds from Issuance of Debt	613,000,000
Amortization of Debt Discount (Premium)		3,000,000
2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Cost of Hedge	$144,800,000

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Finite And Indefinite Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Excluding Goodwill	$86,279,000	$90,030,000
Less: Accumulated Amortization	21,630,000	21,005,000
Intangible assets, net	64,649,000	69,025,000
Goodwill [Roll Forward]
Goodwill at December 31, 2013	190,966,000
Foreign currency translation	-6,242,000
Goodwill at March 31, 2014	184,724,000
Future amortization [Abstract]
2014	9,900,000
2015	7,500,000
2016	6,900,000
2017	5,400,000
2018	4,900,000
Indefinite-Lived Intangible Assets Member
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite life intangibles	8,181,000	8,270,000
Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	78,098,000	81,760,000
Less: Accumulated Amortization	21,630,000	21,005,000
Developed Technology Rights [Member] | Indefinite-Lived Intangible Assets Member
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite life intangibles	4,266,000	4,266,000
Developed Technology Rights [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	32,496,000	33,253,000
Less: Accumulated Amortization	9,982,000	9,185,000
Trademarks [Member] | Indefinite-Lived Intangible Assets Member
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite life intangibles	3,915,000	4,004,000
Trademarks [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	2,737,000	2,798,000
Less: Accumulated Amortization	2,009,000	1,850,000
Distribution Rights [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	250,000	250,000
Less: Accumulated Amortization	200,000	194,000
Licensing Agreements [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	8,233,000	8,234,000
Less: Accumulated Amortization	1,801,000	1,637,000
Customer Relationships [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	26,845,000	27,946,000
Less: Accumulated Amortization	5,095,000	4,636,000
Noncompete Agreements [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	6,766,000	8,508,000
Less: Accumulated Amortization	2,425,000	3,397,000
Other Intangible Assets [Member] | Finite-Lived Intangible Assets [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Definite life intangibles, cost	771,000	771,000
Less: Accumulated Amortization	118,000	106,000
BioMimetics [Member]
Goodwill [Roll Forward]
Goodwill at December 31, 2013	1,336,000
Foreign currency translation	0
Goodwill at March 31, 2014	1,336,000
International Segment [Member]
Goodwill [Roll Forward]
Goodwill at December 31, 2013	16,041,000
Foreign currency translation	-6,242,000
Goodwill at March 31, 2014	9,799,000
UNITED STATES
Goodwill [Roll Forward]
Goodwill at December 31, 2013	173,589,000
Foreign currency translation	0
Goodwill at March 31, 2014	$173,589,000

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Schedule of Accumulated Other Comprehensive Income(Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax	($6,599)		$2,398
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax	0	-2,628
Accumulated Other Comprehensive Income (Loss) [Member]
Schedule of Accumulated Other Comprehensive Income(Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax	-6,599		2,398
Other Comprehensive Income Loss Before Reclassifications Net Of Tax	-8,997
Accumulated Translation Adjustment [Member]
Schedule of Accumulated Other Comprehensive Income(Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax	-6,599		2,398
Other Comprehensive Income Loss Before Reclassifications Net Of Tax	-8,997
Minimum Pension Liability [Member]
Schedule of Accumulated Other Comprehensive Income(Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax	0		0
Other Comprehensive Income Loss Before Reclassifications Net Of Tax	0
Unrealized Gain(Loss) Marketable Securities [Member]
Schedule of Accumulated Other Comprehensive Income(Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax	0		0
Other Comprehensive Income Loss Before Reclassifications Net Of Tax	$0

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Anti-dilutive common stock equivalents excluded from diluted earnings per share computation as a result of net loss	800,000	1,900,000
Weighted-average number of shares outstanding, basic	50,868,000	48,625,000
Common stock equivalents	0	0
Weighted-average number of shares outstanding, diluted	50,868,000	48,625,000
Stock options	1,923,000	159,000
Non-vested shares, restricted stock units, and stock-settled phantom stock units	9,000	31,000
Convertible debt	0	115,000

Commitments_and_Contingencies_

Commitments and Contingencies - Product Liability Contingency (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2013	Sep. 30, 2014	Mar. 31, 2013	Oct. 09, 2014
Product Liability Contingency [Line Items]
Finite-Lived License Agreements, Gross						$4,600,000
Third Party Recovery		10,000,000	5,000,000
Insurance Recovery Cash Spend	25,000,000
Product Liability Costs in Excess of Threshold	2,700,000
PROPHECY [Member]
Product Liability Contingency [Line Items]
Payments for Legal Settlements				900,000
Royalty Guarantees, Commitments, Amount						10,700,000
PROFEMUR Titanium Modular Neck Product [Member]
Product Liability Contingency [Line Items]
Estimated product liability range, minimum	15,000,000
Estimated product liability range, maximum	25,000,000
Product Liability Accrual, Net	15,000,000
Product Liability, current	6,000,000
Product Liability, non current	9,000,000
Increase Decrease in Estimated Recovery from Third Party					19,400,000
Estimated Recovery from Third Party, Current	25,000,000
Maximum Estimated Third Party Recovery	40,000,000
CONSERVE (R) Metal-on-metal [Member]
Product Liability Contingency [Line Items]
Product Liability Contingency, Third Party Recovery	10,900,000
MicroPort [Member] | PROPHECY [Member]
Product Liability Contingency [Line Items]
Payments for Legal Settlements				$13,800,000

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Assets	$1,201,308		$892,676
Net sales	77,934	71,062
Depreciation	5,280	4,346
Operating Income (Loss)	-33,121	-23,046
InventoryStepUpAmortizationExpense	-28	-604
DistributorConversionCharges	-24	-542
Business Combination, Acquisition Related Costs, Transition Costs	-11,024	-7,402
Interest Expense Income, Net	7,649	4,136
Other Nonoperating Income (Expense)	5,312	15,286
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	-46,082	-42,468
Payments to Acquire Property, Plant, and Equipment	11,854	7,836
Capital Expenditures, Continuing Operations		7,836
UNITED STATES
Segment Reporting Information [Line Items]
Assets	449,283		450,055
Net sales	57,486	48,951
Depreciation	3,020	2,297
Sales Revenue Goods Net Percent Change	17.40%
AmortizationExpenseWithoutDistributorConversion	2,059	1,096
Segment Operating Loss	2,371	5,679
Payments to Acquire Property, Plant, and Equipment	10,746
Capital Expenditures, Continuing Operations		5,200
International Segment [Member]
Segment Reporting Information [Line Items]
Assets	98,425		94,412
Net sales	20,448	22,111
Depreciation	768	641
AmortizationExpenseWithoutDistributorConversion	470	577
Segment Operating Loss	-3,125	803
Payments to Acquire Property, Plant, and Equipment	1,055
Capital Expenditures, Continuing Operations		733
BioMimetics [Member]
Segment Reporting Information [Line Items]
Assets	19,885		17,924
Net sales	0	0
Depreciation	37	108
AmortizationExpenseWithoutDistributorConversion	61	77
Segment Operating Loss	-3,244	-3,391
Payments to Acquire Property, Plant, and Equipment	28
Capital Expenditures, Continuing Operations		2
Europe [Member]
Segment Reporting Information [Line Items]
Net sales	12,248	13,742
Sales Revenue Goods Net Percent Change	-10.90%
Other Geographical Areas [Member]
Segment Reporting Information [Line Items]
Net sales	8,200	8,369
Sales Revenue Goods Net Percent Change	-2.00%
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Assets	633,715		330,285
Net sales	0	0
Depreciation	1,455	1,195
AmortizationExpenseWithoutDistributorConversion	0	0
Segment Operating Loss	-18,047	-17,589
Payments to Acquire Property, Plant, and Equipment	25
Capital Expenditures, Continuing Operations		1,901
Segment [Member]
Segment Reporting Information [Line Items]
Number of Reportable Segments	3
Assets	1,201,308		892,676
Net sales	77,934	71,062
Depreciation	5,280	4,241
Sales Revenue Goods Net Percent Change	9.70%
AmortizationExpenseWithoutDistributorConversion	2,590	1,750
Segment Operating Loss	($22,045)	($14,498)